Table 1.
Baseline Characteristics of Participants
| Variable | Early ART (n = 34) | Later ART (n = 32) | Untreated (n = 37) | HIV-Negative Controls (n = 19) |
|---|---|---|---|---|
| Age, median (IQR), y | 37.3 (33.8–42.2) | 36.6 (34.7–43) | 33.4 (27.3–36.5) | 37.6 (30.2–42) |
| Male, No. (%) | 33 (97) | 32 (100) | 36 (97) | 16 (84) |
| MSM, No. (%) | 33 (97) | 32 (100) | 36 (97) | 15 (79) |
| Recent IVDU, No. (%) | 0 | 0 | 2 (5) | 4 (21) |
| Baseline CD4+ T-cell count, median (IQR), cells/µL | 533 (434–742) | 562 (499–704) | 580 (514–676) | … |
| Baseline plasma HIV RNA level (IQR), log10 copies/mL | 5.2 (4.5–5.7) | 4.2 (3.5–4.7) | 4.2 (3.3–5.0) | … |
| Duration of HIV infection at diagnosis, median (IQR), mo | 2.4 (0.8–2.4) | 2.4 (2.4–2.4) | 2.4 (2.4–2.4) | … |
| Immediate pre-ART CD4+ T-cell count (IQR), cells/µL | 533 (434–742) | 325 (246–435) | … | … |
| Immediate pre-ART plasma HIV RNA level (IQR), log10 copies/mL | 4.8 (4.3–5.5) | 4.7 (4.0–5.0) | … | … |
| Duration of observation during ART (IQR), y | 2.8 (1.8–4.6) | 2.3 (1.8–3.3) | … | … |
| Total duration of observation (IQR), y | 3.0 (2.0–4.7) | 6.1 (4.8–7.7) | 3.5 (2.4–4.4) | … |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; IVDU, intravenous drug use; MSM, men who have sex with men.